Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma

Journal of Clinical Oncology

Volumn 26, Issue 15, 2008, Pages 2489-2496

  Brizel, David M ^a   Murphy, Barbara A ^b   Rosenthal, David I ^b   Pandya, Kishan J ^b   Glück, Stefan ^b   Brizel, Herbert E ^b   Meredith, Ruby F ^b   Berger, Dietmar ^b   Chen, Mon Gy ^b   Mendenhall, William ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; PALIFERMIN; PLACEBO; ANTINEOPLASTIC AGENT; KERATINOCYTE GROWTH FACTOR;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADULT; AGED; AMYLASE BLOOD LEVEL; ANEMIA; ANXIETY DISORDER; ARTICLE; BODY WEIGHT; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEHYDRATION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHAGIA; DYSPNEA; FATIGUE; FEMALE; FEVER; FOLLOW UP; GRANULOCYTOPENIA; HEAD AND NECK CARCINOMA; HEADACHE; HUMAN; HYPOMAGNESEMIA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PAIN; PANCREATITIS; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; SCHISTOSOMIASIS; SIDE EFFECT; SPUTUM; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VOMITING; XEROSTOMIA; CANCER STAGING; COMPARATIVE STUDY; DRUG COMBINATION; HEAD AND NECK TUMOR; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FIBROBLAST GROWTH FACTOR 7; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MUCOSITIS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE;

EID: 45149120776     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.13.7349     Document Type: Article

References (30)

1. Vera-Llonch M, Oster G, Hagiwara M, et al: Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma. Cancer 106:329-336, 2006
2. Bellm LA, Cunningham G, Durnell L, et al: Defining clinically meaningful outcomes in the evaluation of new treatments for oral mucositis: Oral mucositis patient provider advisory board. Cancer Invest 20:793-800, 2002
3. Peterman A, Cella D, Glandon G, et al: Mucositis in head and neck cancer: Economic and quality-of-life outcomes. J Natl Cancer Inst Monogr, 2001, pp 45-51
4. Nguyen NP, North D, Smith HJ, et al: Safety and effectiveness of prophylactic gastrostomy tubes for head and neck cancer patients undergoing chemoradiation. Surg Oncol 15:199-203, 2006
5. Adelstein DJ, Li Y, Adams GL, et al: An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21:92-98, 2003
6. Brizel DM, Albers ME, Fisher SR, et al: Hyper-fractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 338:1798-1804, 1998
7. Denis F, Garaud P, Bardet E, et al: Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radichemotherapy for advanced-stage oropharynx carcinoma: Comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems. Int J Radiat Oncol Biol Phys 55:93-98, 2003
8. Carter DL, Hebert ME, Smink K, et al: Double blind randomized trial of sucralfate vs placebo during radical radiotherapy for head and neck cancers. Head Neck 21:760-766, 1999
9. Epstein JB, Silverman S Jr, Paggiarino DA, et al: Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: Results from a multicenter, randomized, double-blind, placebo-controlled clinical trial. Cancer 92:875-885, 2001
10. Makkonen TA, Bostrom P, Vilja P, et al: Sucralfate mouth washing in the prevention of radiation-induced mucositis: A placebo-controlled double-blind randomized study. Int J Radiat Oncol Biol Phys 30:177-182, 1994
11. Meredith R, Salter M, Kim R, et al: Sucralfate for radiation mucositis: Results of a double-blind randomized trial. Int J Radiat Oncol Biol Phys 37: 275-279, 1997
12. Pfeiffer P, Madsen EL, Hansen O, et al: Effect of prophylactic sucralfate suspension on stomatitis induced by cancer chemotherapy: A randomized, double-blind cross-over study. Acta Oncol 29:171-173, 1990
13. Sonis ST: A biological approach to mucositis. J Support Oncol 2:21-32, 2004
14. Trotti A, Garden A, Warde P, et al: A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. Int J Radiat Oncol Biol Phys 58:674-681, 2004
15. Finch PW, Rubin JS, Miki T, et al: Human KGF is FGF-related with properties of a paracrine effector of epithelial cell growth. Science 245:752-755, 1989
16. Rubin JS, Osada H, Finch PW, et al: Purification and characterization of a newly identified growth factor specific for epithelial cells. Proc Natl Acad Sci U S A 86:802-806, 1989
17. Finch PW, Rubin JS: Keratinocyte growth factor/fibroblast growth factor 7, a homeostatic factor with therapeutic potential for epithelial protection and repair. Adv Cancer Res 91:69-136, 2004
18. Finch PW, Rubin JS: Keratinocyte growth factor expression and activity in cancer: Implications for use in patients with solid tumors. J Natl Cancer Inst 98:812-824, 2006
19. Amgen Inc: Kepivance® (palifermin) prescribing information. Thousand Oaks, CA, 2006
20. Brizel DM, Herman T, Goffinet D, et al: A phase I/II trial of escalating doses of recombinant human keratinocyte growth factor (rHuKGF) in head & neck cancer (HNC) patients receiving radiotherapy with concurrent chemotherapy (CCT). Int J Radiat Oncol Biol Phys 51:40, 2001 (abstr 67)
21. Stokman MA, Sonis ST, Dijkstra PU, et al: Assessment of oral mucositis in clinical trials: Impact of training on evaluators in a multi-centre trial. Eur J Cancer 41:1735-1738, 2005
22. Anderson SJ: Some thoughts on the reporting of adverse events in phase II cancer clinical trials. J Clin Oncol 24:3821-3822, 2006
23. Scharf O, Colevas AD: Adverse event reporting in publications compared with sponsor database for cancer clinical trials. J Clin Oncol 24:3933-3938, 2006
24. Trotti A, Pajak TF, Gwede CK, et al: TAME: Development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group. Lancet Oncol 8:613-624, 2007
25. Spielberger R, Stiff P, Bensinger W, et al: Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 351:2590-2598, 2004
26. Zia-Amirhosseini P, Salfi M, Leese P, et al: Pharmacokinetics, pharmacodynamics, and safety assessment of palifermin (rHuKGF) in healthy volunteers. Clin Pharmacol Ther 79:558-569, 2006
27. Brizel DM, Wasserman TH, Henke M, et al: Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18:3339-3345, 2000
28. Wasserman T, Mackowiak JI, Brizel DM, et al: Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. Int J Radiat Oncol Biol Phys 48:1035-1039, 2000
29. Wasserman TH, Brizel DM, Henke M, et al: Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and-neck cancer: 2-year follow-up of a prospective, randomized, phase III trial. Int J Radiat Oncol Biol Phys 63:985-990, 2005
30. Ning S, Shui C, Khan WB, et al: Effects of keratinocyte growth factor on the proliferation and radiation survival of human squamous cell carcinoma cell lines in vitro and in vivo. Int J Radiat Oncol Biol Phys 40:177-187, 1998